{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:34:24Z","timestamp":1789565664868,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Novel oral poliovirus vaccine (OPV) type 2 (nOPV2) has been made available for outbreak response under an emergency use listing authorization based on supportive clinical trial data. Since 2021 more than 350 million doses of nOPV2 were used for control of a large outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2) in Nigeria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using a bayesian time-series susceptible-infectious-recovered model, we evaluate the field effectiveness of nOPV2 immunization campaigns in Nigeria compared with campaigns using monovalent OPV type 2 (mOPV2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found that both nOPV2 and mOPV2 campaigns were highly effective in reducing transmission of cVDPV2, on average reducing the susceptible population by 42% (95% confidence interval, 28\u201354%) and 38% (20\u201351%) per campaign, respectively, which were indistinguishable from each other in this analysis (relative effect, 1.1 [.7\u20131.9]). Impact was found to vary across areas and between immunization campaigns.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results are consistent with the comparable individual immunogenicity of nOPV2 and mOPV2 found in clinical trials but also suggest that outbreak response campaigns may have small impacts in some areas requiring more campaigns than are suggested in current outbreak response procedures.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiad222","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T09:55:18Z","timestamp":1687773318000},"page":"805-812","source":"Crossref","is-referenced-by-count":21,"title":["Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria"],"prefix":"10.1093","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6242-7796","authenticated-orcid":false,"given":"Arend","family":"Voorman","sequence":"first","affiliation":[{"name":"The Bill & Melinda Gates Foundation , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hil","family":"Lyons","sequence":"additional","affiliation":[{"name":"The Bill & Melinda Gates Foundation , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Shuaib","sequence":"additional","affiliation":[{"name":"National Primary Health Care Development Agency , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman S","family":"Adamu","sequence":"additional","affiliation":[{"name":"National Primary Health Care Development Agency , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Korir","sequence":"additional","affiliation":[{"name":"World Health Organization, Nigeria Country Office , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesfaye","family":"Erbeto","sequence":"additional","affiliation":[{"name":"World Health Organization, Nigeria Country Office , Abuja , Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-2001","authenticated-orcid":false,"given":"Ananda S","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"The Bill & Melinda Gates Foundation , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Okiror","sequence":"additional","affiliation":[{"name":"The Bill & Melinda Gates Foundation , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"key":"2024031408462440500_jiad222-B1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1586\/14760584.2016.1140041","article-title":"Polio endgame: the global switch from tOPV to bOPV","volume":"15","author":"Garon","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2024031408462440500_jiad222-B2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the type 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"issue":"suppl 1","key":"2024031408462440500_jiad222-B3","first-page":"A122","article-title":"Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): novel oral polio vaccine type 2 (nOPV2) experience","volume":"41","author":"Macklin","year":"2022","journal-title":"Vaccine"},{"key":"2024031408462440500_jiad222-B4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.15585\/mmwr.mm7124a2","article-title":"Genetic characterization of novel oral polio vaccine type 2 viruses during initial use phase under emergency use listing\u2014worldwide, March\u2013October 2021","volume":"71","author":"Martin","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024031408462440500_jiad222-B5","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S1473-3099(22)00582-5","article-title":"A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story","volume":"23","author":"Bandyopadhyay","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024031408462440500_jiad222-B6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(22)01582-3","article-title":"Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use","volume":"400","author":"Hill","year":"2022","journal-title":"Lancet"},{"key":"2024031408462440500_jiad222-B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(20)32541-1","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials","volume":"397","author":"De Coster","year":"2021","journal-title":"Lancet"},{"key":"2024031408462440500_jiad222-B8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(20)32540-X","article-title":"Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials","volume":"397","author":"S\u00e1ez-Llorens","year":"2021","journal-title":"Lancet"},{"key":"2024031408462440500_jiad222-B9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"Lancet"},{"key":"2024031408462440500_jiad222-B10","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/clinids\/13.5.926","article-title":"Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review","volume":"13","author":"Patriarca","year":"1990","journal-title":"Rev Infect Dis"},{"key":"2024031408462440500_jiad222-B11","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(07)60531-5","article-title":"Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study","volume":"369","author":"Grassly","year":"2007","journal-title":"Lancet"},{"key":"2024031408462440500_jiad222-B12","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJMoa0803259","article-title":"Effectiveness of immunization against paralytic poliomyelitis in Nigeria","volume":"359","author":"Jenkins","year":"2008","journal-title":"N Engl J Med"},{"key":"2024031408462440500_jiad222-B13","doi-asserted-by":"crossref","first-page":"e917","DOI":"10.1016\/S2214-109X(23)00116-X","article-title":"Poliovirus antibodies following two rounds of campaigns with a type 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey","volume":"11","author":"Kennedy","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2024031408462440500_jiad222-B14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2002468","article-title":"Assessing the stability of polio eradication after the withdrawal of oral polio vaccine","volume":"16","author":"Famulare","year":"2018","journal-title":"PLoS Biol"},{"key":"2024031408462440500_jiad222-B15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/oxfordjournals.aje.a120717","article-title":"Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter","volume":"86","author":"Benyesh-Melnick","year":"1967","journal-title":"Am J Epidemiol"},{"key":"2024031408462440500_jiad222-B16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/infdis\/jiab507","article-title":"Fecal shedding of 2 novel live attenuated oral poliovirus type 2 vaccine candidates by healthy infants administered bivalent oral poliovirus vaccine\/inactivated poliovirus vaccine: 2 randomized clinical trials","volume":"226","author":"Gast","year":"2021","journal-title":"J Infect Dis"},{"key":"2024031408462440500_jiad222-B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00139-1","article-title":"Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial","author":"Wilkinson","journal-title":"Lancet Infect Dis"},{"key":"2024031408462440500_jiad222-B18","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/JVI.02954-12","article-title":"Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in Northern Nigeria","volume":"87","author":"Burns","year":"2013","journal-title":"J Virol"},{"key":"2024031408462440500_jiad222-B19","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/infdis\/jiy389","article-title":"Boosting of mucosal immunity after fractional-dose inactivated poliovirus vaccine","volume":"218","author":"Gamage","year":"2018","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"2024031408462440500_jiad222-B20","first-page":"A85","article-title":"Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine","volume":"41","author":"Voorman","year":"2022","journal-title":"Vaccine"},{"key":"2024031408462440500_jiad222-B21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107042","article-title":"Disaggregating census data for population mapping using random forests with remotely-sensed and ancillary data","volume":"10","author":"Stevens","year":"2015","journal-title":"PLoS One"},{"key":"2024031408462440500_jiad222-B22","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1073\/pnas.1818433116","article-title":"Decreasing measles burden by optimizing campaign timing","volume":"116","author":"Thakkar","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024031408462440500_jiad222-B23","article-title":"Estimating efficacy of measles supplementary immunization activities via discrete-time modeling of disease incidence time series","author":"Dong","journal-title":"arXiv"},{"key":"2024031408462440500_jiad222-B24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s12879-016-1817-3","article-title":"A spatial model of wild poliovirus type 1 in Kano State, Nigeria: calibration and assessment of elimination probability","volume":"16","author":"McCarthy","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2024031408462440500_jiad222-B25","doi-asserted-by":"crossref","first-page":"S176","DOI":"10.1093\/infdis\/175.Supplement_1.S176","article-title":"Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature","volume":"175","author":"Alexander","year":"1997","journal-title":"J Infect Dis"},{"key":"2024031408462440500_jiad222-B26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(12)60648-5","article-title":"The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001\u201311: a retrospective analysis","volume":"380","author":"O\u2019Reilly","year":"2012","journal-title":"Lancet"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad222\/50929349\/jiad222.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/3\/805\/56967291\/jiad222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/3\/805\/56967291\/jiad222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T08:51:36Z","timestamp":1710406296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/3\/805\/7207511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6,26]]},"published-print":{"date-parts":[[2024,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad222","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,15]]},"published":{"date-parts":[[2023,6,26]]}}}